公开(公告)号：EP1475443B1

公开(公告)日：2010-11-03

申请号：EP04075152.1

申请日：1998-02-13

申请人： VIROGENETICS CORPORATION

发明人： Tartaglia, James ,  Cox, William I. ,  Gettig, Russell Robert ,  Martinez, Hector ,  Paoletti, Enzo ,  Pincus, Steven E.

IPC分类号： C12N15/64 ,  C12N15/67 ,  C12N15/86 ,  A61K48/00

CPC分类号： C12N15/86 ,  A61K48/00 ,  C12N15/67 ,  C12N15/85 ,  C12N2710/24043 ,  C12N2710/24143 ,  C12N2830/00 ,  C12N2830/60 ,  C12N2840/00

公开(公告)号：EP1925662A1

公开(公告)日：2008-05-28

申请号：EP07023799.5

申请日：1996-06-06

申请人： VIROGENETICS CORPORATION

发明人： Paoletti, Enzo ,  Pincus, Steven E. ,  Cox, William I. ,  Kauffman, Elizabeth B.

IPC分类号： C12N7/01 ,  A61K39/285 ,  A61K39/275 ,  A61K39/245 ,  C07K16/08 ,  C12P21/02

CPC分类号： C07K16/088 ,  A61K39/00 ,  C07K14/005 ,  C12N2710/16122 ,  C12N2710/24022 ,  C12N2710/24122 ,  C12N2760/20122

摘要： Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. The DNA of the recombinant viruses can be used as probes or for generating PCR primers.

摘要翻译： 公开并要求保护含有编码HCMV抗原的DNA的减毒重组病毒，以及使用病毒，来自其的表达产物和由病毒或表达产物产生的抗体的方法和组合物。 重组病毒可以是NYVAC或ALVAC重组病毒。 来自其的重组病毒和基因产物以及由病毒和基因产物产生的抗体具有几种预防，治疗和诊断用途。 重组病毒的DNA可用作探针或产生PCR引物。

公开(公告)号：EP1475443A3

公开(公告)日：2004-12-01

申请号：EP04075152.1

申请日：1998-02-13

申请人： VIROGENETICS CORPORATION

发明人： Tartaglia, James ,  Cox, William I. ,  Gettig, Russell Robert ,  Martinez, Hector ,  Paoletti, Enzo ,  Pincus, Steven E.

IPC分类号： C12N15/64 ,  C12N15/67 ,  C12N15/86 ,  A61K48/00

CPC分类号： C12N15/86 ,  A61K48/00 ,  C12N15/67 ,  C12N15/85 ,  C12N2710/24043 ,  C12N2710/24143 ,  C12N2830/00 ,  C12N2830/60 ,  C12N2840/00

摘要： Disclosed and claimed are vectors having enhanced expression and methods for making and using them. Enhancement of expression is from substantially cotemporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid molecule encodes a transcription factor or a translation factor or a transcription factor and a translation factor. The contemporaneous expression can be from operably linking the first and second nucleic molecules to a single promoter, or from operably linking the first nucleic acid molecule to a first promoter and the second nucleic molecule to a second promoter wherein the first and second promoters function substantially contemporaneously. Thus, the first and second nucleic molecules can be at the same locus in the vector, or at different loci. The second nucleic acid can encode: one transcription factor or more than one transcription factor; or one translation factor or more than one translation factor; or at least one transcription factor and at least one translation factor. The transcription factor can be from vaccinia H4L, D6, A7, G8R, A1L, A2L, H5R, or combinations thereof. The translation factor can be from a K3L open reading frame, an E3L open reading frame, a VAI RNA, an EBER RNA, a sigma 3 open reading frame, a TRBP open reading frame, or combinations thereof. The vector can be a poxvirus such as an attenuated poxvirus, e.g., NYVAC, or ALVAC.

公开(公告)号：EP1475443A2

公开(公告)日：2004-11-10

申请号：EP04075152.1

申请日：1998-02-13

申请人： VIROGENETICS CORPORATION

发明人： Tartaglia, James ,  Cox, William I. ,  Gettig, Russell Robert ,  Martinez, Hector ,  Paoletti, Enzo ,  Pincus, Steven E.

IPC分类号： C12N15/64 ,  C12N15/67 ,  C12N15/86 ,  A61K48/00

CPC分类号： C12N15/86 ,  A61K48/00 ,  C12N15/67 ,  C12N15/85 ,  C12N2710/24043 ,  C12N2710/24143 ,  C12N2830/00 ,  C12N2830/60 ,  C12N2840/00

摘要： Disclosed and claimed are vectors having enhanced expression and methods for making and using them. Enhancement of expression is from substantially cotemporal expression of at least one first nucleic acid molecule and at least one second nucleic acid molecule. The second nucleic acid molecule encodes a transcription factor or a translation factor or a transcription factor and a translation factor. The contemporaneous expression can be from operably linking the first and second nucleic molecules to a single promoter, or from operably linking the first nucleic acid molecule to a first promoter and the second nucleic molecule to a second promoter wherein the first and second promoters function substantially contemporaneously. Thus, the first and second nucleic molecules can be at the same locus in the vector, or at different loci. The second nucleic acid can encode: one transcription factor or more than one transcription factor; or one translation factor or more than one translation factor; or at least one transcription factor and at least one translation factor. The transcription factor can be from vaccinia H4L, D6, A7, G8R, A1L, A2L, H5R, or combinations thereof. The translation factor can be from a K3L open reading frame, an E3L open reading frame, a VAI RNA, an EBER RNA, a sigma 3 open reading frame, a TRBP open reading frame, or combinations thereof. The vector can be a poxvirus such as an attenuated poxvirus, e.g., NYVAC, or ALVAC.

摘要翻译： 公开并要求保护的是具有增强的表达和制备和使用它们的方法的载体。 表达的增强是从至少一个第一核酸分子和至少一个第二核酸分子的基本上cotemporal表达。 第二核酸分子编码转录因子或翻译因子或转录因子和翻译因子。 所述同期表达式可以是从所述第一和第二核酸分子可操纵地连接于一个启动子，或从所述第一核酸分子可操作地连接到第一启动子和所述第二核酸分子与第二个启动子worin所述第一和第二启动子的功能基本同时 ， 因此，第一和第二核酸分子可以是在载体中的相同位点，或在不同的位点。 第二核酸可以编码：一个转录因子或多于一个的转录因子; 或一个翻译因子或一个以上的翻译因子; 或至少一个转录因子和至少一个翻译的因素。 转录因子可以是从牛痘H4L，D6，A7，G8R，A1L，A2L，H5R，或它们的组合。 平移因子可以是来自K3L开放阅读框，以E3L开放阅读框，一个VAI RNA的RNA EBER，西格玛3的开放阅读框，一个TRBP开放阅读框，或者它们的组合。 所述载体可以是痘病毒：如减毒痘病毒，E. G.，NYVAC或ALVAC。